Fetal Bovine Serum Market

Market Overview:

The global fetal bovine serum market size reached US$ 948.0 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,333.3 Million by 2028, exhibiting a growth rate (CAGR) of 5.75% during 2023-2028.

Fetal bovine serum (FBS) is a major component of animal cell culture media, which is obtained from bovine fetuses of cows. It has several nutritional and macromolecular factors that are essential for cell growth. Besides this, it also comprises amino acids, sugars, lipids, hormones, and low gamma globulin content. As a result, it is widely utilized in a range of applications, such as providing essential nutrients and facilitating cell survival and proliferation in eukaryotic cell culture. It is also used in research, manufacturing, biotech drugs, and controlling human and veterinary vaccines.

Fetal Bovine Serum Market Trends:

FBS finds application in generating stem cells for treating patients suffering from acute and chronic lung damage due to coronavirus disease (COVID-19). In addition, as it contains growth factors and antibodies that can be utilized in laboratories to keep cells alive for dividing, growing, and evolving, it plays a pivotal role in various scientific research. This, along with significant growth in the research and development (R&D) activities on account of increasing funding by governing and private agencies to introduce novel biopharmaceuticals, is catalyzing the demand for FBS worldwide. Furthermore, the escalating demand for biopharma products on account of the growing prevalence of acute and chronic diseases is contributing to the growth of the market. Apart from this, the emerging trend of nuclear families and inflating income levels are positively influencing pet ownership and humanization, which is resulting in the increasing adoption of companion animals across the globe. This, along with the rising consumption of animal-derived products, is anticipated to fuel the need for FBS in veterinary diagnostics and vaccines to prevent infectious diseases around the world.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global fetal bovine serum market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and end user.

Breakup by Product:

• Charcoal Stripped
• Chromatographic
• Dialyzed Fetal Bovine Serum
• Exosome Depleted
• Stem Cell
• Others
   

Breakup by Application:

• Biopharmaceuticals
• Cell Culture
• Human and Animal Vaccine Production
• Others
   

Breakup by End User:

• Biotechnology and Pharmaceutical Companies
• Academic Institutes
• Research Laboratories
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Atlas Biologicals Inc., Biological Industries (Sartorius AG), Bio-Techne Corporation, BioWest, Bovogen Biologicals Pty Ltd., General Electric Company, HiMedia Laboratories, Merck KGaA, PAN-Biotech, Rocky Mountain Biologicals, TCS Biosciences Ltd and Thermo Fisher Scientific Inc.

Report Coverage: